Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
EC

NASDAQ · ECOR

electroCore, Inc.

Healthcare · Medical - Devices

$9.62

Up+$0.43 (+4.68%)

Updated Sep 13, 2026, 2:23 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.09M
P/E ratio
-3.07
Dividend yield
0.00%
52-week range
$4.41 – $10.95
Volume
40.22K
Avg. volume
53.04K

Price performance

ECOR price history

1M range · 19 trading sessions · Daily adjusted prices

ECOR closed at $9.62 after 19 trading sessions, down 6.15% for the selected period.

Last close
$9.62
Period change
-6.15%
Period low
$8.99
Period high
$10.81
Daily close
View OHLC price history
ECOR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$9.185$9.99$9.185$9.6240.22K
Sep 10, 2026$8.70$9.40$8.70$9.1985.45K
Sep 9, 2026$8.90$9.19$8.90$8.9926.98K
Sep 8, 2026$9.08$9.19$8.87$9.0824.2K
Sep 4, 2026$9.18$9.41$9.02$9.2119.96K
Sep 3, 2026$9.50$9.7026$8.96$9.2132.75K
Sep 2, 2026$9.09$9.63$8.75$9.5182.22K
Sep 1, 2026$9.32$9.55$8.995$9.05180.06K
Aug 31, 2026$9.51$9.87$9.20$9.4996.43K
Aug 28, 2026$9.63$9.9898$9.22$9.62587.12K
Aug 27, 2026$10.59$10.67$9.66$9.7164.1K
Aug 26, 2026$9.45$10.35$9.45$10.3578.01K
Aug 25, 2026$9.56$9.9699$9.23$9.47109.29K
Aug 24, 2026$10.52$10.52$9.48$9.6545.55K
Aug 21, 2026$10.33$10.95$10.00$10.5259.94K
Aug 20, 2026$10.70$10.81$9.64$10.21182.66K
Aug 19, 2026$10.35$10.93$9.8501$10.8174.45K
Aug 18, 2026$10.26$10.54$10.02$10.2747.23K
Aug 17, 2026$10.15$10.68$10.00$10.25144.33K

Latest ECOR news

The latest Smart Investors Daily articles mentioning ECOR.

Stock researchCompany · Overview

ECOR research

Overview

Company profile and research snapshot.

Company profile

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ECOR recent ratings
DateFirmRatingTarget
Jan 26, 2026HC Wainwright & Co.Buy—
Mar 13, 2025Ladenburg ThalmannBuy—
Mar 13, 2025HC Wainwright & Co.Buy—
Dec 18, 2024HC Wainwright & Co.Buy—
Mar 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers

Internal leadership appointments reflect the Company's confidence in two exceptional leaders whose complementary strengths will enhance shareholder valueROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, ef

Yahoo · Sep 7, 2026

Ecora Royalties PLC Announces Change of Registered Office Address

LONDON, UK / ACCESS Newswire / September 7, 2026 / Ecora (LSE:ECOR)(TSX:ECOR)(OTCQX:ECRAF), announces that its registered office has changed with immediate effect. The Company's new registered office address is: Carrington House 1st Floor West 126 - 130 Regent Street London W1B 5SEAll other Company contact details, including telephone numbers and website address, remain unchanged.

Yahoo · Sep 3, 2026

Ecora Royalties PLC Announces Investor Presentation via Engage Investor

LONDON, UK / ACCESS Newswire / September 3, 2026 / Ecora (LSE/TSX:ECOR)(OTCQX:ECRAF) is pleased to announce that the leadership team will host a live interactive presentation to discuss the recent 2026 Half Year Results on the Engage Investor platform, on Thursday 10th September 2026, at 2pm BST.Ecora welcomes all current shareholders and interested investors to join and encourages investors to pre-submit questions.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By